Rapid Opioid Countermeasure System “ROCS”
Designed for Military Personnel &
Chemical Incident Responders
COMPACT
DURABLE
RELIABLE
Product Highlights
Temporary prophylaxis of respiratory and/or central nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids such as fentanyl analogues.
- Only naloxone product with two indications – post exposure and temporary prophylactic use ahead of mission
- Approved by the U.S. Food and Drug Administration (FDA) in February 2022
- Highest FDA-approved dosage as countermeasure against high-potency opioids
- Issued NATO Stock Number #6505-01-699-8878
- Naloxone Auto-Injector (NAI) 10 mg passes U.S. Department of Defense military standard durability tests3
- First to meet FDA draft guidance standard for 99.999% device reliability
- For those outside the U.S.; the product is available to allied foreign military services through the U.S. Department of Defense (FMS) or through direct sales via expanded access approval exclusively for government or military use.
Designed in Partnership with U.S. Department of Defense
“Access to a point-of-injury countermeasure such as the 10 mg naloxone autoinjector is a major step forward to protect and maintain the readiness of the Joint Force”
– COL Ryan R. Eckmeier, U.S. Army